Seminars in Oncology Nursing
Volume 22 , Pages 20-27 , February 2006

Administration of Anti-EGFR Therapy: A Practical Review

  • Taline Khoukaz

      Affiliations

    • Corresponding Author InformationAddress correspondence to Taline Khoukaz, RN, ACNP-C, 1441 Eastlake Ave, Suite 3455, Los Angeles, CA 90033

References 

  1. Iressa . Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2003; [package insert]
  2. Tarceva [package insert]. Melville, NY. OSI Pharmaceuticals, Inc; South San Francisco, CA: Genentech, Inc; 2004.
  3. Shepherd FA , Pereira J , Ciuleanu TE , et al.   A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial . [abstract 7022] J Clin Oncol . 2004;22(suppl):
  4. Giaccone G , Herbst RS , Manegold C , et al.   Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer (A phase III trial—INTACT 1) . J Clin Oncol . 2004;22:777–784
  5. Herbst RS , Giaccone G , Schiller JH , et al.   Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer (A phase III trial—INTACT 2) . J Clin Oncol . 2004;22:785–794
  6. Cohen MH , Williams GA , Sridhara R , et al.   FDA drug approval summary (Gefitinib (ZD1839) (Iressa) tablets) . Oncologist . 2003;8:303–306
  7. Takano T , Ohe Y , Kusumoto M , et al.   Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non–small cell lung cancer treated with gefitinib . Lung Cancer . 2004;45:93–104
  8. Inoue A , Saijo Y , Maemondo M , et al.   Severe acute interstitial pneumonia and gefitinib . Lancet . 2003;361:137–139
  9. Erbitux [package insert]. New York, NY. ImClone Systems Inc; Princeton, NJ: Bristol-Myers Squibb; 2005.
  10. Nagaria NC , Cogswell J , Choe JK , et al.   Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis . J Clin Oncol . 2005;23:2423–2424
  11. Zanotti KM , Markman M . Prevention and management of antineoplastic-induced hypersensitivity reactions . Drug Safety . 2001;24:767–779
  12. Ream MA , Tunison D . Hypersensitivity reactions . In:  Yasko JM editors. Nursing Management of Symptoms Associated with Chemotherapy . Bala Cynwyd, PA: Meniscus Health Care; 2001;p. 213–224
  13. Gammon D , Bhargava P , McCormick MJ . Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol . Oncologist . 2004;9:546–549
  14. Choi J , Harnett P , Fulcher DA . Carboplatin desensitization . Ann Allergy Asthma Immunol . 2004;93:137–141
  15. Lee CW , Matulonis UA , Castells MC . Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity (standard protocol effective in 57 patients for 255 courses) . Gynecol Oncol . 2005;99:393–399
  16. Confino-Cohen R , Fishman A , Altaras M , et al.   Successful carboplatin desensitization in patients with proven carboplatin allergy . Cancer . 2005;104:640–643
  17. Feldweg AM , Lee CW , Matulonis UA , et al.   Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel (A new standard protocol used in 77 successful treatments) . Gynecol Oncol . 2005;96:824–829
  18. Mis L , Fernando NH , Hurwitz HI , et al.   Successful desensitization to oxaliplatin . Ann Pharmacother . 2005;39:966–999
  19. Bonosky K , Miller R . Hypersensitivity reactions to oxaliplatin (What nurses need to know) . Clin J Oncol Nurs . 2005;9:325–330

 Supported in part by a grant from Bristol-Myers Squibb Company.

PII: S0749-2081(06)00035-0

doi: 10.1016/j.soncn.2006.01.012

Seminars in Oncology Nursing
Volume 22 , Pages 20-27 , February 2006

Article Tools

* Image Usage & Resolution